Division of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine, Ludlow Faculty Research Building #203, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea.
Pancreaticobiliary Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Seoul, South Korea.
J Gastrointest Surg. 2019 Jun;23(6):1180-1187. doi: 10.1007/s11605-018-4041-1. Epub 2018 Nov 21.
The purpose of this study was to validate the predictive value of the oncologic outcome in addition to the validation of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) surgical risk calculator in patients treated with pancreaticoduodenectomy (PD) or pylorus-preserving pancreaticoduodenectomy (PPPD) for pancreatic head cancer.
From June 2005 to December 2014, 199 patients underwent PD or PPPD for pancreatic head cancer. Medical records were retrospectively reviewed for investigating general patient characteristics and any comorbid diseases. The calculated perioperative complication risks from the ACS NSQIP calculator were compared with observed complication rates. In a propensity score matching analysis, disease-free survival (DFS) and overall survival (OS) were estimated according to calculated severe complication rate (CSCR).
The CSCR > 17.9% (n = 69) and CSCR < 17.9% (n = 130) groups were significantly different considering number of the retrieved lymph nodes (22.95 ± 14.0 vs 18.80 ± 10.1, p = 0.029), histologic grade (p = 0.0235), and incidence of lymphovascular invasion (p = 0.026). The CSCR < 17.9% group had longer DFS (17.0 vs. 11.0 months, p = 0.015), but the OS was similar between the groups (39.0 vs. 23.0 months, p = 0.48). In the 1:2 propensity score analysis, the CSCR < 17.9% group had longer DFS and OS (DFS 26.0 vs. 11.0 months, p = 0.009; OS 44.0 vs. 26.0 months, p = 0.023).
The ACS NSQIP surgical risk calculator predicts surgical risk in patients with pancreatic head cancer who undergo PD or PPPD. Furthermore, this tool can help predict the prognosis of surgically treated pancreatic head cancer.
本研究旨在验证美国外科医师学会国家外科质量改进计划(ACS NSQIP)手术风险计算器在接受胰头癌胰十二指肠切除术(PD)或保留幽门的胰十二指肠切除术(PPPD)治疗的患者中的肿瘤学结局预测价值,并对其进行验证。
2005 年 6 月至 2014 年 12 月,199 例胰头癌患者接受 PD 或 PPPD 治疗。回顾性分析病历以调查一般患者特征和任何合并症。比较 ACS NSQIP 计算器计算的围手术期并发症风险与观察到的并发症发生率。在倾向评分匹配分析中,根据计算的严重并发症发生率(CSCR)估计无病生存率(DFS)和总生存率(OS)。
CSCR>17.9%(n=69)和 CSCR<17.9%(n=130)组在检出的淋巴结数量(22.95±14.0 与 18.80±10.1,p=0.029)、组织学分级(p=0.0235)和脉管侵犯发生率(p=0.026)方面差异有统计学意义。CSCR<17.9%组的 DFS 更长(17.0 与 11.0 个月,p=0.015),但两组 OS 无差异(39.0 与 23.0 个月,p=0.48)。在 1:2 倾向评分分析中,CSCR<17.9%组的 DFS 和 OS 更长(DFS 26.0 与 11.0 个月,p=0.009;OS 44.0 与 26.0 个月,p=0.023)。
ACS NSQIP 手术风险计算器可预测接受 PD 或 PPPD 治疗的胰头癌患者的手术风险。此外,该工具可帮助预测接受手术治疗的胰头癌患者的预后。